key: cord-0921173-ys8cs84y
authors: Dijkstra, Johannes M.; Hashimoto, Keiichiro
title: Expected immune recognition of COVID-19 virus by memory from earlier infections with common coronaviruses in a large part of the world population
date: 2020-04-23
journal: F1000Res
DOI: 10.12688/f1000research.23458.1
sha: ddfb9792224ce1cec3356bcc5d119cc578c0a407
doc_id: 921173
cord_uid: ys8cs84y

SARS-CoV-2 is the coronavirus agent of the COVID-19 pandemic causing high mortalities. In contrast, the widely spread human coronaviruses OC43, HKU1, 229E, and NL63 tend to cause only mild symptoms. The present study shows, by in silico analysis, that these common human viruses are expected to induce immune memory against SARS-CoV-2 by sharing protein fragments (antigen epitopes) for presentation to the immune system by MHC class I. A list of such epitopes is provided. The number of these epitopes and the prevalence of the common coronaviruses suggest that a large part of the world population has some degree of specific immunity against SARS-CoV-2 already, even without having been infected by that virus. For inducing protection, booster vaccinations enhancing existing immunity are less demanding than primary vaccinations against new antigens. Therefore, for the discussion on vaccination strategies against COVID-19, the available immune memory against related viruses should be part of the consideration.

Prevalence and associated disease of the common human coronaviruses 229E, NL63, OC43, and HKU1 The Centers for Disease Control and Prevention (CDC; https:// www.cdc.gov/coronavirus/general-information.html) states: "Common human coronaviruses, including types 229E, NL63, OC43, and HKU1, usually cause mild to moderate upper-respiratory tract illnesses, like the common cold. Most people get infected with one or more of these viruses at some point in their lives." The same agency lists the common symptoms caused by these viruses as runny nose, sore throat, headache, fever, cough, and general feeling of being unwell, but also explains that they occasionally cause lower-respiratory tract illnesses, such as pneumonia or bronchitis. The viruses 229E and OC43 have been known since the 1960s (reviewed in Kahn & McIntosh, 2005) , but NL63 (van der Hoek et al., 2004 ) and HKU1 (Woo et al., 2005) were only (conclusively) identified following the rise in interest in coronaviruses in the wake of the SARS epidemy. These common coronaviruses are believed to be the second most common cause of the common cold (Mäkelä et al., 1998) . In the U.S.A., a 3-year RT-PCR surveillance of respiratory samples of patients revealed that the four viruses 229E, NL63, OC43, and HKU1 were present at levels varying by season and region, with all individual viruses peaking at >3% prevalence in each investigated region (Midwest, Northeast, South, West); co-infection with other coronaviruses was found in only ~2% of infected cases, but co-infection with another respiratory virus was found in a substantial ~30% of infected cases (Killerby et al., 2018) . This pattern was reminiscent of findings in the United Kingdom Since immune memory protection can be induced by related pathogens, as exemplified by the eradication of human smallpox virus (Variola) by immunization with a related "cowpox" virus (Vaccinia) (Plotkin & Plotkin, 2018), it is interesting to consider whether common human coronavirus infections may have induced some level of protection against SARS-CoV-2.

The possibility of matching linear epitopes between SARS-CoV-2 and the common human coronaviruses that may stimulate the immune system through MHC class I presentation The two major arms of immune memory concern antibody secretion by B cells and killing of infected cells by CD8 + T cells. For a coronavirus infection in mouse, both immune responses were needed to efficiently control the virus (reviewed by Weiss & Navas-Martin, 2005). Based on theoretical considerations alone, it is difficult to predict effective B cell memory across different virus species (Qiu et al., 2020), and very recent experiments concluded that sera from people that likely had been infected with the common human coronaviruses 229E, NL63, OC43, and/or HKU1, possessed no or negligible cross-reactivity with SARS-CoV-2 virus S protein (Amanat et al., 2020) and thus probably possess no neutralizing antibodies. However, for inducing CD8 + T cell memory, the core requirement is merely that an identical peptide is presented by major histocompatibility complex (MHC) class I (MHC-I) molecules. MHC-I molecules present peptide fragments from intracellular proteins, thus also from viral proteins, at the cell surface for screening by CD8 + cytotoxic T cells (Neefjes et al., 2011) . CD8 + T cells recognize the combination of MHC-I molecule with peptide by T cell receptors (TCR) that are unique per T cell clone, and if stimulated these clones can proliferate, kill the presenting (virus-infected) cell, and produce memory cells. MHC-I molecules are polymorphic in that they are represented by many diverse allelic forms that differ between human populations and individuals (Robinson et al., 2020), and mostly bind 9 amino acids (aa) length in their binding groove which is closed at either end (Bjorkman et al., 1987; Rammensee et al., 1995; Schellens et al., 2015) .

In the present study, we analyzed whether there are linear 9 aa epitopes that are identical between proteins encoded by SARS-CoV-2 and one or more of the common human coronaviruses. We found many of such epitopes indeed, and, by using prediction software, found that some are expected to bind well to certain MHC-I alleles. We therefore expect that common human coronaviruses can induce some level of CD8 + T cell-mediated immune memory recognizing SARS-CoV-2, and consider the possibility of enhancing that immune memory by vaccination. ) by performing BLAST homology searches at the NCBI database (https://blast.ncbi.nlm.nih.gov/ Blast.cgi) and by making multiple sequence alignments using CLUSTALW software (https://www.genome.jp/tools-bin/clustalw); continuous stretches of 9 aa acids identical between SARS-CoV-2 and one of the other viruses were identified manually. All these shared 9 aa epitopes were screened by ANN 4.0 software at IEDB Analysis Resource (http://tools.immuneepitope. org/mhci/) for prediction of their affinity to a set of representative human MHC-I alleles. Table 1 lists the 9 aa epitopes that are identical between proteins encoded by SARS-CoV-2 and one or more of the common human coronaviruses. Many identical >9 aa stretches were found with ORF1ab encoded polyprotein, one such identical stretch (of 12 aa) was found with the N protein of the other two type II coronaviruses HCoV-OC43 and HCoV-HKU1, and no such stretches were found when comparing with any of the other gene products; ORF1ab-derived mature proteins with such stretches, expected from cleavage of the polyprotein precursor (Wu et al., 2020), were the transmembrane protein nonstructural protein 4 (NSP4), 3C-like cysteine protease NSP5, RNA binding protein NSP9, RNA dependent RNA polymerase NSP12, helicase NSP13, 3'-to-5' exonuclease NSP14, nidoviral endoribonuclease specific for U NSP15, and S-adenosylmethionine-dependent ribose 2'-O-methyltransferase NSP16 (Table 1) . Sequence alignment figures of the ORF1ab and N proteins are shown in Extended data (Dijkstra, 2020) with highlighting of the interesting epitopes. It is of note that the S protein, which is the prime candidate for inducing neutralizing antibodies (Cohen, 2020), is not suitable for inducing an MHC-I-restricted immune memory across the investigated viral species as between S protein of SARS-CoV-2 and S proteins of the common human coronaviruses there are no 9 aa or even 8 aa matches (not shown). Table 1 shows that there are >200 linear epitopes of 9 aa that are identical between SARS-CoV-2 and at least one of the common human coronaviruses, most of them with OC43 and HKU1 which, like SARS-CoV-2, belong to the group II coronaviruses. In a simplified model, if people would have been exposed to many of these epitopes through common HCoV infections, this kind of equals immunization by a small intracellular protein under natural viral infection conditions. Whereas live virus is commonly considered the gold standard in regard to inducing strong immunity, unless the virus has some tricks up its sleeve to manipulate the immune system, which for common human coronaviruses is not well investigated, a research grant proposal suggesting this as a vaccination strategy would probably fail. Reviewers of such proposal would righteously point out that the strategy would not induce neutralizing antibodies, which for combating some viral infections can be very important, and that for inducing MHC-I-restricted cellmediated cytotoxicity memory, ideally, a much larger protein or more proteins should be taken. Those reviewers would conclude that for such small intracellular protein to induce strong immune memory it would need too much luck in regard to immunogenicity and it would be too dependent on the MHC alleles of the immunized person as different alleles bind different peptides. Nevertheless, those reviewers would probably also agree that in most persons thus vaccinated some (small) level of immune memory protection would be established, even with such small non-surface protein (e.g. Polakos et al., 2001) . Regardless of that this obviously is not the ideal way to induce a population-wide strong protective immunity (see the spread of COVID-19), together with other factors such as health and the number of encountered viruses (the strength of the viral challenge), the induced immune memory could make a difference for whether a person gets sick; at the population scale, it so may somewhat reduce the virus reproduction number. Importantly, by stimulating this HCoV-derived MHC-I restricted immune memory by vaccination (see below), it could become a more significant helper in fighting COVID-19.

Based on combinations of experimental results and computer learning, various software has been created that with some degree of reliability can predict how efficiently peptides can bind to the grooves of various MHC-I alleles. In the present study we used the artificial neural network ( Table 1 shows these expected affinities for twelve MHC-I alleles that are rather representative for sets of MHC-I alleles with similar binding properties (supertypes) and so represent a large part of the human MHC-I binding repertoire 2008) found that a SARS-CoV-1 15 aa peptide sequence (their "Replicase 4701-4715" peptide) encompassing the SARS-CoV-2/HCoVshared ORF1ab4725 and ORF1ab4726 epitopes that are predicted to bind well to the MHC-I alleles HLA-A*0201 and HLA-B*3901 (see our Table 1 ) was associated with a CD8 + T cell response against SARS-CoV-1 in humans. However, Li et al. (2008) also found such CD8 + T cell response associated with a SARS-CoV-1 15 aa peptide (their "Nucleocapsid 106-120" peptide) encompassing the SARS-CoV-2/HCoV-shared N 106, N 107, N 108, an N 109 epitopes for which our analyses did not predict MHC-I binding (see our Table 1 ).

The MHC-I binding affinity is considered the most selective in determining which peptides are presented, but also steps in the Table 1 . Stretches of 9 consecutive amino acids that are identical between SARS-CoV-2 and at least one of the common human coronaviruses. Nucleocapsid YFYYLGTGP peptide processing and loading pathways may play selective roles which are difficult to capture in prediction software (Nielsen et al., 2005) . We argue that, if such steps would be selective for presentation, in most cases they would probably not differentiate between the 9 aa epitope in the SARS-CoV-2 context versus the respective HCoV context, since most of those epitopes are within stretches that also show many similarities in the neighboring residues (Extended data).

Not all stable complexes of MHC-I with non-self peptides elicit a strong immune response, but "immunogenicity" features are hard to predict with meaningful reliability by in silico analysis (Calis et al., 2013) , and in the present study we refrain from such predictions. Table 1 should, foremost, be understood as evidence of principle and a list of promising peptides, whereas only future experiments can prove MHC-I-mediated immune memory involving these or other peptides.

In regard to SARS-CoV-2 recognition, the common human coronaviruses may also induce some MHC-II-mediated immune memory by CD4 + helper T cells (for shared epitope use by different coronaviruses see Zhao et al., 2016) . CD4 + helper T cells can help stimulate cells involved in antibody or cellmediated cytotoxic immune responses (Neefjes et al., 2011) . However, for this topic we refrained from detailed (software) predictions because comparison of MHC-II epitopes across different viruses is harder than for MHC-I epitopes. Namely, although the core of MHC-II bound peptides is also only 9 aa, the surrounding amino acids are also part of the bound peptide that tends to be 12-25 aa (Brown et al., 1993; Rammensee et al., 1995; Stern & Wiley, 1994) and can affect how the peptide interacts with the receptors on the CD4 + helper T cells (Arnold et al., 2002) .

Immune memory means that a secondary immune response, upon renewed encounter with the same pathogen, is faster and stronger than the primary immune response during the first encounter with the pathogen. This is based on expansion of specific B and T cell clones, which specifically recognize pathogen(-derived) epitopes, with some of those cells becoming memory cells (Paul, 2013) . This principle also causes that for a booster vaccination/immunization the requirements for efficiently inducing an immune response are lower than for a first vaccination/immunization (e.g. Goding, 1996) . Especially in elderly people, who have a decreased ability to mount adaptive immune responses against new antigens, vaccination that stimulates an immune memory response may be beneficial (Reber et al., 2012) . As discussed above, people's past infections with common coronaviruses probably did not induce a B cell memory for making antibodies that can neutralize SARS-CoV-2. However, as the current study shows by analysis of linear 9 aa epitopes, these common human coronaviruses are expected to induce CD8 + T cells that may potentially kill SARS-CoV-2-infected cells and so can help eradicate the virus. There are several possible ways to exploit this probable immune memory. For example, if using RNA for immunization (Cohen, 2020), it may be best to also include SARS-CoV-2 genes that encode MHC-I epitopes that match those of the common coronaviruses. Alternatively, delivery of these epitopes to the MHC-I presentation system may be tried by peptide or protein based vaccines (e.g. Kohyama et al., 2009; Slingluff, 2011; van Montfoort et al., 2014; Yadav et al., 2014) , possibly in combination with some of the strategies that are currently being explored for non-specific stimulation of the immune system against COVID-19 (Kupferschmidt & Cohen, 2020). Protein (-coding) vaccines, for example encompassing a large part of the SARS-CoV-2 ORF1ab product, would have an advantage over peptide-vaccines by including multiple possible MHC-I and also MHC-II epitopes, and be less dependent on MHC-allele matching and the quality of software predictions. Naturally, as for any new vaccine strategy, it should be carefully assessed whether the benefits of the induced type of immunity outweigh the potential deleterious health effects caused by an increased inflammation response (Cohen, 2020; Weingart et al., 2004). Important questions are also whether the history of previousespecially recent-infections with common coronaviruses, or people's MHC alleles, affect people's resistance to SARS-CoV-2. Most definitely, if discussing possible strategies for vaccination against SARS-CoV-2, pre-existing MHC-I-based immunity derived from previous infections with common coronaviruses should be part of the consideration.

Although we were not aware of this at the time of writing, a recent preprint appeared with overlapping contents (Nguyen et al., 2020) . I think the Table could be made quite a lot smaller and thus more valuable to the reader. The source proteins could be indicated as an abbreviation provided in the legend as could the various seasonal strains. The boxes could then be quite small, and either be positive or negative. In any case, an effort should be made to condense this table.

Is the study design appropriate and is the work technically sound? Yes

Are all the source data underlying the results available to ensure full reproducibility? Yes

No competing interests were disclosed.

1.

3.

As authors already mentioned in their manuscript the similar study by Nguyen A. et al (JVI, 2020 ) demonstrated the HLA binding affinity of all possible 8-to 12-mers from SARS-CoV-2 proteome. This group found that HLA-B15:03 type has the greatest capacity to present highly conserved peptides which are shared among coronaviruses suggesting a cross-protective T cell immune response. In current manuscript using different prediction software authors identified and showed the sequence of epitopes which bind well to similar HLA type, HLA-B15:01. Interestingly, one of the epitopes (YLRKHFSM) can be bound by 4 different HLA types. The obvious strength of this study is the demonstration that certain epitopes, which are identical between SARS-CoV-2 and the common human coronaviruses are being predicted as high affinity binders in multiple HLA-A and B types.

Overall, the work reports important new details about SARS-CoV-2 epitopes theoretically being recognized by human CD8+ T cells. Undeniably, future experiments can prove if generated memory immune responses are specific to the proposed epitopes.

There are some suggestions:

The analysis of p/MHCI binding for HLA-C type (if available) would certainly complete the list of presented epitopes

The introduction part subtitled: "The possibility of matching linear epitopes…" has missing information about previously published reports regarding T cell response in individuals infected with coronaviruses, either common or SARS-CoV.

In the discussion part readers may wonder why the authors did not discuss their findings with those already published (although they may not have been out at the time of submission) but should be included in the revision.

Especially the data on the protective effects against common coronaviruses by previous infections by homologous virus are relevant. In the F1000Research publication system, two or three reviewers will comment on-line, after which we as authors (probably) have to modify the manuscript following their comments. If those comments are in line with yours, we can implement some of the information that you provided. Having said that, we also like to keep the message simple and concentrate on the MHC-I restricted immune memory against SARS-CoV-2 that can be expected to already exist in many people as induced by common coronaviruses

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original Attribution License work is properly cited.

Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, NY, 14642, USA David H. Smith Center for Vaccine Biology and Immunology, Rochester, NY, USA These analyses of potential cross reactive CD8 T cell epitopes between the current SARS-CoV-2 and "seasonal" endemic human CoV is useful and timely and the discussion is balanced.There are several modifications that I believe would improve the clarify and value of the manuscript.Based on the first sentence of the paragraph entitled "the possibility of matching linear epitopes…", the authors sate that the two major arms of immune memory…are antibody and CD8 T cells" I believe this is incorrect, as CD4 T cells can directly impact lung pathology and contribute to both protective and pathological immune responses. In fact a recent paper uploaded to BioRxiv suggested that it was populations in the CD4 T cell compartments that correlated with disease severity. The authors should acknowledge that all three subsets of the adaptive response (B cells, CD8 and CD4 T cells) are likely to be important, but this manuscript focusses on CD8 epitopes.The authors refer to the "software owners" when describing cutoffs. They are perhaps better described as software "designers".When discussing "Vaccine Potential", the authors state that the secondary response is "faster and stronger". This should be more accurately described, with some references, in a way that points out the higher frequency of responding cells during memory recall, and lower thresholds of TcR engagement needed for T cell activation, both qualities that contribute to a competitive advantage of memory cells.Because the nature of CD8 memory to the different antigens screened by the authors is not known, the epitopes identified may or may not be targets of cross reactive memory recall. Therefore, the word "expected" should be substituted for "Potential" or some other word that indicates that the epitope list includes candidates but not expected epitopes.I think the This manuscript reports a very useful study that extends our knowledge of peptide-MHC recognition by CD8+ T cells during emerging virus infections such as SARS-CoV-2. Detailed analysis showed in silico the presence of potential epitopes shared between new types of betacoronavirus: SARS-CoV-2 and common human alphacoronaviruses: OC43, HKU1, 229E and NL63. Due to the high prevalence of the common coronaviruses authors suggest that the large part of the human population has already some degree of specific memory T cell response before having been infected with the virus.

No competing interests were disclosed. Competing Interests:

We confirm that we have read this submission and believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. Dear Colleagues, I am in the middle of writing a similar paper and I would like you to take in consideration the following data that will make my paper unnecessary ( I do not need any additional paper for my career) if it was added to your interesting article. 1) data on serological cross reaction among the Coronavirus that last for a while. (For à review ; and I have more papers https://www.medrxiv.org/content/10.1101/2020.04.14.20065771v1.full.pdf including challenged studies in volunteer with old corona viruses, ; https://academic.oup.com/jid/article/219/12/1913/5307035

) 2)CD4 data in a https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2271881/pdf/epidinfect00023-0213.pdf BioRxiv paper in healthy blood donors in Germany that cross with SARS-COV-2 peptides ( ) and cross CD4 peptides https://www.medrxiv.org/content/10.1101/2020.04.17.20061440v1.full.pdf among new coronavirses ( ) 3) https://pubmed.ncbi.nlm.nih.gov/27287409/?from_term=Coronavirus+cross+protection&from_pos=6 The hypothesis that these immune cross reactions ( CD8, CD4, antibodies) prevent colonization of SARS-COV-2 in children aged 0-9 years who are permanently infected in kinder garden and primary school with these old common cold corona viruses. These children do not seem, as a result, able to contaminate neither siblings nor parents. The remaining immune memory would also explain why children aged 10-19 years who can be infected, do not usually develop any invasive serious disease caused by SARS-COV-2 but are able to infect other children and adults. Likewise, it would explain why the COVID19 clinical presentation is worsening with age.I hope you will consider my remarks and integrate these data into your paper and it could be then a very comprehensive article on the subject of potential cross protection between the different beta Coronavirus. sincerely yours, H. Bercovier.

The benefits of publishing with F1000Research:Your article is published within days, with no editorial bias You can publish traditional articles, null/negative results, case reports, data notes and moreThe peer review process is transparent and collaborative Your article is indexed in PubMed after passing peer review Dedicated customer support at every stage For pre-submission enquiries, contact research@f1000.com